Business Context and Reporting Period
Puma Biotechnology, Inc. filed this Form 8-K on December 7, 2018, to disclose the creation of a direct financial obligation. The company is a Delaware corporation headquartered in Los Angeles, California.
Key Financial Metrics and Debt Obligations
The filing details a new borrowing event rather than periodic financial performance metrics such as revenue or cash flow.
- New Debt: Borrowed $30.0 million under the "Term B Loan" on December 7, 2018.
- Existing Debt: Previously borrowed $125.0 million under the "Term A Loan" (May 8, 2018).
- Total Term Loans: $155.0 million aggregate principal.
- Interest Rate: The greater of 8.25% or (Prime Rate + 3.5%).
- Maturity Date: May 1, 2023.
- Final Payment: Upon repayment, a final payment equal to 7.5% of the original principal amount is required.
- Repayment Schedule: Interest-only payments through July 1, 2020; principal and interest payments thereafter.
Material Changes and Covenants
The primary material change is the increase in indebtedness by $30.0 million. The Loan Agreement imposes specific financial and operational covenants:
- Revenue Covenants: The company must achieve product revenue on a trailing 3-month basis that is at least 70% of its 2018 board-approved revenue target and at least 50% of its 2019 board-approved revenue target.
- Negative Covenants: Restrictions on incurring additional indebtedness, mergers, acquisitions, paying dividends, and selling assets.
- Prepayment Penalties: Fees of 3.0% (first year), 2.0% (second year), and 1.0% (third year) apply to voluntary prepayments.
- Events of Default: Include failure to pay, covenant breaches, insolvency, or judgments exceeding $500,000. Default triggers a 5.0% interest rate penalty and potential foreclosure on collateral, including cash.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance or management commentary on future outlook beyond the loan terms. Key risks identified include:
- Liquidity Risk: The company is restricted from incurring additional indebtedness without lender consent.
- Performance Risk: Failure to meet the specific revenue thresholds relative to board-approved projections constitutes a default.
- Collateral Risk: The loan is secured by the company's assets, including cash, which could be foreclosed upon in the event of default.
Investor Verification Checklist
- Verify the company's current product revenue against the 70% (2018) and 50% (2019) covenant thresholds.
- Confirm the total outstanding principal balance of $155.0 million and the accrued interest obligations.
- Review the board-approved revenue projections referenced in the covenants to assess compliance risk.
- Assess the impact of the 7.5% final payment requirement on the total cost of capital.
- Check for any subsequent filings regarding covenant waivers or amendments to the Loan Agreement.